Embed Size (px)
Citation preview
Judith Caron, Programs Director, CQDMMay 2014
2014 CQDM/CIHR COLLABORATIVE FUNDING PROGRAM IN PERSONALIZED MEDICINE TO ACCELERATE DRUG DISCOVERY
Our mission
To fund support breakthrough technologies that will significantly enhance biopharmaceutical R&D productivity and accelerate the development of safer and more efficacious drugs
To create a collaborative ground between the academic and private sectors based on trust, creativity and mutual benefit
THE ONLY PRE-COMPETITIVE PHARMA CONSORTIUM IN CANADA
Pfizer
AstraZeneca
Merck
Lilly
No
vartis
Boehringer
Canada
Québec
GS
K
A COLLABORATIVE APPROACH TO SHARE THE R&D COSTS AND THE RESULTS
Each pharma member hasa non-exclusive end-user licence option for R&D • Fully paid-up • Worldwide• Perpetual
This model allows• High financial leverage (10- 20 fold)• To derisk R&D• To improve R&D productivity
OUR FUNDING PROGRAMS
Focus Large scaleMultidisciplinaryImmediate impact on drug discovery
ExploreHighly innovative Disruptive technologiesEarly concept validation
Québec/OntarioLarge scaleCollaboration QC/ONImmediate impact
Québec/FranceLarge scaleCollaboration QC/FrImmediate impact
Québec/Massasuchetts Large scale Collaboration QC/Mass Late stage R&D
Pan CanadianLarge scaleCanadian networkImmediate impact
Focus on technologies that accelerate drug discovery
$2M / project $300 k / project
$1M / project
$2M / project
$1.4M / project
$1.5M / project
Completed 18 competitionswithin 6 funding programs450 projects reviewed
Established an international mentorship program (over 80 mentors)
Raised $65 M of public and private funding
Built a strong R&D ecosystem including pharmas, SEMs and academia
HIGHLIGHTS
OUR PORTFOLIO
A network of 400 researchers
A clear focus on Scientific excellence and innovation Strong impact on biopharmaceutical research Translational research Multidisciplinary approach Public/private partnerships
32 research projects for a total of $37,3M
46 research entities• 25 academic institutions • 21 private companies
Several different sectors of activityEngineering – imaging – photonics – nanotechnologies – instrumentations – biomarker development – discovery platforms – drug delivery
SEVERAL THERAPEUTIC INDICATIONS
Across many sectors of activities
Genomics System biology InformaticsChemistryEngineeringBiomaterials ImagingDiagnosticPhysics
Medical devices
Pharmacology BiochemistryCell Biology Clinical sciencesProteomicsNanotechnologyBiophysicsPhysiology
Each project is assigned a mentor from each pharma sponsor
The mentors are international experts from the global Pharma organizations
The mentors meet with the investigators twice a year, on site, and provide guidance on how to deliver results with highest impact
They can provide some additional resources (clinical samples, database, specific expertise)
The mentors become the champions of the funded projects in their respective corporate organizations
THE MENTORSHIP PROGRAM: A WIN/WIN COMBINATION
A network of 80 mentors
RIGHTS FOR CQDM PHARMA MEMBERS
Results Deliverables
New IPKnow howDataCopyrightsNo new IP
Owned by Researchers and
Research Entities
Background IP
CQDMproject
R&D use
Fully paid-up, perpetual, worldwide licence option to use deliverables for R&D
Results – data – process - technology - platformService agreement with the PI (when relevant)
OUR ACHIEVEMENTS
32 outstanding research projects engaging $37.3M• 10 projects completed with a success rate of 90%
• 80% of the technology already used by the pharma members
• 3 major investments by pharma members to use the results at the end of the project
• Success stories of great value for biopharmaceutical research
• HTS discovery platform for VLP vaccine antigens
• Biomarkers for monitoring beta cells mass and function in diabetes patients
• Biosensors for GPCR signaling pathways
• Early diagnosis of pulmonary hypertension
• ERG for non invasive stratification of psychiatric disorders
• Flash walk mapping for GPRCs
• Synthetic lethality in oncology
• Several tangibles economic benefits for Quebec and Canada• Support of 256 jobs• Technology maturation for 12 SMEs• 25 partnerships with industry• Creation of 5 starts-up• Additional $14.5 M from industry
CQDM/CIHR COLLABORATIVE FUNDING PROGRAM IN PERSONALIZED MEDICINE TO ACCELERATE DRUG DISCOVERY
SCOPE OF THE CQDM/CIHR PROGRAM
• This pan-Canadian program offer public and private partners the opportunity to work together to develop novel technologies and tools that address current and critical challenges faced by the pharmaceutical industry in the area of personalized medicine.
• To develop cutting-edge next-generation technologies, computational tools and devices with an immediate and strong impact on the discovery/development of new drugs
Not intended to fund the development of specific molecules Not intended to fund the discovery of biomarkers with ‘’omics’’
approaches
RESEARCH AGENDA
Research projects focused on the invention and development of next-generation of technologies, computational tools and devices in the following research areas: cancer infection and immunity neurodegeneration affecting cognition
No technologies/tools/devices funded through other initiatives in personalized medicine
Broad range of research fields/disciplines: biological and health sciences, chemistry, engineering, nanotechnologies, computational sciences, medical devices, imaging, biosensors, in silico and in vitro screening systems, and improved disease-relevant animal models, etc.
Well-defined near-term application with potential to significantly impact biopharmaceutical R&D
• Research performed in Canada
• Academic sector: laboratories, affiliated research institutes, hospitals
• Private sector: SMEs, biotechs, CROs
• Public/private partnerships mandatory: minimum 1 academic researcher
and 1 industrial researcher working collaboratively
• Address most important challenges of the biopharmaceutical industry
• Highly innovative projects with strong and wide potential impact on the
pharmaceutical drug R&D process and the Canadian healthcare system
• Multinational pharmaceutical companies not eligible to receive funds
ELIGIBILITY
• Duration: Up to 30 months
• Funds available: $750K maximum
• Private matching funds: 25% of total project cost (in cash, in kind, combination)
• Eligible costs: Salary of research personnel; Material and supplies; Travel expenses; Intellectual property costs; Administrative costs (up to 15% for the CQDM portion). CIHR’s policies and general guidelines, including those specific to overhead costs, will apply to its contribution
• Non-eligible costs: Equipment or facilities; Salary of the principal investigator and co-investigators
FUNDING SPECIFICS
REVIEW AND DECISION PROCESS
Scientific evaluationExternal review committee
CQDM/CIHR joint committee
Board
Final selection
Research agreement
Projects start
LOI Full applications
Fit program + matching funds requirements
Scientific evaluationExternal review committee
Fund in order of scientific merit 3-step process: CQDM/CIHR joint committee to
decide before Scientific evaluation
16
CQDM/CIHR joint committee
CQDM/CIHR joint committee
IMPACT IMPACT
• Scientific excellence and novelty
• Potential of applications in drug researcho immediate impact on drug discovery or drug developmento capacity to address important unmet needs
• Clear well-defined deliverables and milestones
• Global competitiveness
• Team expertise/experience
• Quality of collaboration
• Alignment with corporate objectives of the private partner(s)
EVALUATION CRITERIA OF THE FULL PROPOSALS
IMPACT ON THE DRUG R&D PROCESS
• Identify most important challenges currently faced by the pharmaceutical industry
• How will you project address them?
• How will the expected results and the deliverables of the project impact the drug R&D process? Please specifically discuss the following possible impacts (if applicable): Opening new therapeutic approaches and research avenues Bringing more effective medicines to the clinic and to the market Increasing the efficacy of existing drugs Reducing the R&D costs, time to market or the risks of
development Other impacts on the drug discovery and development process
POSITIONING/GLOBAL COMPETITIVENESS
• Not about the team or facilities• It’s all about the technology, product, tool, device• Identify: Current state of the art Competition:o Direct and indirecto Local and internationalo Existing or in development
• Compare your technology, product, tool, device• Bring out:
Advantages Differentiating factors Originality and novelty aspects
MANAGEMENT OF FUNDED PROJECTS
• Projects are deliverables-based and milestones driven
• Research agreement included:
Semi-annual milestones Deliverables Detailed budget Gantt chart: major steps, milestones, deliverables, budget
• Ensure success of project
... mutual benefits for researchers and CQDM pharma members
• Minimally one pharma mentor Opportunity for researchers to create strong links
and collaborate with pharma industry
Two meetings/year (co-ordinated by CQDM)
Informal interactions throughout year
• Mentors role? Ensure technology developed fully aligned with
industry needs
Eager to aid with project success in mind (not to evaluate)
May provide additional resources (clinical samples, database, specific expertise)
MENTORSHIP PROGRAM: ONE OF A KIND
TIMELINES CQDM/CIHR 2014 COMPETITION
Important dates
Program launch March 18th, 2014
Deadline for submission of the letters of intent June 27th, 2014
Announcement of the selected letters of intent September 11th, 2014
Deadline to submit full proposals November 27th, 2014
Final selection announcement March 31st, 2015
Signature of a research agreement Three months window
Funding release and beginning of the projects July 1st, 2015
EXAMPLES OF DELIVERABLES
Software for data analysis or data measurement
Diagnostic tools
Imaging tools
Medical devices or instruments
Prototypes
Delivery systems
Predictive algorithms
Etc......
EXAMPLES OF PROJECTS
http://www.cqdm.org/en/projects-portfolio/
CancerRichard KremerPlatform for the enrichment of CTCs to follow disease progression/treatment outcome
Infection & ImmunityMichel BergeronProfiling the gut microbiome to predict the emergence of antibiotic resistance
Neurodegeneration affection cognitionRick HogeProfiling patients with AD using a new MRI technique
CONTACT INFORMATION
Thank you for your participation!
Merci de votre attention!
Olivier Jacob-GravelProgram Delivery [email protected]
Etienne RicherAssistant DirectorCIHR Institute of [email protected]
More information:
http://www.cqdm.org
http://cqdm.org/en/programs-and-competitions/cqdm-cihr-competition.php
http://www.cihr-irsc.gc.ca/e/48082.html
Judith CaronDirector of [email protected]
